Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
MRUS Merus NV
- Stocks
- Healthcare
- NASDAQ: MRUS
Price (delayed)
$41.56
Market cap
$2.88B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.08
Enterprise value
$2.69B
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed
Highlights
Merus's gross profit has surged by 88% QoQ and by 47% YoY
The revenue has surged by 88% since the previous quarter and by 47% year-on-year
Merus's equity has soared by 71% YoY but it has decreased by 8% from the previous quarter
Merus's quick ratio has decreased by 14% QoQ but it has increased by 5% YoY
Merus's net income has plunged by 85% YoY and by 29% from the previous quarter
The EPS has contracted by 47% YoY and by 22% from the previous quarter
Key stats
What are the main financial stats of MRUS
Market
Valuations
Earnings
Shares outstanding
69.21M
Market cap
$2.88B
Enterprise value
$2.69B
Price to earnings (P/E)
N/A
Price to book (P/B)
4.82
Price to sales (P/S)
42.25
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
39.61
Revenue
$67.89M
Gross profit
$67.89M
Operating income
-$287.84M
Net income
-$277.34M
EBIT
-$299.23M
EBITDA
-$296.78M
Free cash flow
-$239.68M
Per share
Balance sheet
Liquidity
EPS
-$4.08
EPS diluted
-$4.08
Free cash flow per share
-$3.47
Book value per share
$8.63
Revenue per share
$0.98
TBVPS
$10.57
Total assets
$730.92M
Total liabilities
$134.8M
Debt
$9.86M
Equity
$596.12M
Working capital
$433.14M
Debt to equity
0.02
Current ratio
5.86
Quick ratio
5.3
Net debt/EBITDA
0.63
Margins
Efficiency
Dividend
EBITDA margin
-437.2%
Gross margin
100%
Net margin
-408.5%
Operating margin
-424%
Return on assets
-34.1%
Return on equity
-41.2%
Return on invested capital
-85.8%
Return on capital employed
-46.6%
Return on sales
-440.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MRUS stock price
How has the Merus stock price performed over time
Intraday
3.69%
1 week
1.61%
1 month
-0.84%
1 year
-7.69%
YTD
-1.17%
QTD
-1.26%
Financial performance
How have Merus's revenue and profit performed over time
Revenue
$67.89M
Gross profit
$67.89M
Operating income
-$287.84M
Net income
-$277.34M
Gross margin
100%
Net margin
-408.5%
Merus's gross profit has surged by 88% QoQ and by 47% YoY
The revenue has surged by 88% since the previous quarter and by 47% year-on-year
Merus's net income has plunged by 85% YoY and by 29% from the previous quarter
MRUS's operating income has shrunk by 81% YoY and by 6% QoQ
Price vs fundamentals
How does MRUS's price correlate with its fundamentals
Growth
What is Merus's growth rate over time
Valuation
What is Merus stock price valuation
P/E
N/A
P/B
4.82
P/S
42.25
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
39.61
The EPS has contracted by 47% YoY and by 22% from the previous quarter
Merus's equity has soared by 71% YoY but it has decreased by 8% from the previous quarter
The P/B is 15% more than the 5-year quarterly average of 4.2 and 2.6% more than the last 4 quarters average of 4.7
The revenue has surged by 88% since the previous quarter and by 47% year-on-year
The P/S is 40% lower than the last 4 quarters average of 70.1 but 28% higher than the 5-year quarterly average of 33.0
Efficiency
How efficient is Merus business performance
The ROS has grown by 33% from the previous quarter but it has contracted by 28% YoY
The ROA has declined by 20% since the previous quarter and by 3% year-on-year
The ROE has contracted by 17% from the previous quarter but it has grown by 7% YoY
The ROIC has contracted by 14% YoY and by 8% from the previous quarter
Dividends
What is MRUS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MRUS.
Financial health
How did Merus financials performed over time
Merus's total assets has increased by 47% YoY but it has decreased by 7% from the previous quarter
Merus's quick ratio has decreased by 14% QoQ but it has increased by 5% YoY
MRUS's debt is 98% smaller than its equity
Merus's equity has soared by 71% YoY but it has decreased by 8% from the previous quarter
MRUS's debt to equity is down by 33% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.